Seeking Alpha

Novartis' (NVS) omalizumab meets all primary and secondary endpoints in a pivotal Phase 3 study...

Novartis' (NVS) omalizumab meets all primary and secondary endpoints in a pivotal Phase 3 study in patients with chronic spontaneous urticaria. The study is the second of three pivotal trials designed to test the efficacy and safety of the treatment. The drug — which, if approved for the new indication, would be the only treatment available for the condition outside of antihistamines — is being developed with Genentech (RHHBY.OB). NVS +0.86% premarket. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs